Treatment of systemic sclerosis

Area of Science:

• Rheumatology
• Clinical Pharmacology
• Systemic Sclerosis Research

Background:

• Progressive systemic sclerosis (PSS) management requires improved methods for evaluating drug efficacy.
• Past disease-modifying drug trials in scleroderma have yielded disappointing outcomes.
• Existing treatments offer symptomatic relief for specific PSS complications.

Purpose of the Study:

• To highlight the need for standardized clinical trial guidelines in PSS.
• To review current therapeutic approaches for PSS manifestations.
• To emphasize the importance of evidence-based treatment strategies for scleroderma.

Main Methods:

• Review of existing literature on clinical trials in progressive systemic sclerosis.
• Analysis of current treatment outcomes for esophagitis, Raynaud's phenomenon, and scleroderma renal crisis.
• Identification of knowledge gaps in PSS treatment, particularly for lung involvement.

Main Results:

• Omeprazole has significantly improved esophagitis treatment.
• Calcium channel blockers and iloprost are effective for Raynaud's phenomenon.
• Angiotensin-converting enzyme inhibitors are crucial for managing scleroderma renal crisis.
• Optimal treatment for rapidly progressive scleroderma lung disease remains undetermined.

Conclusions:

• Standardized guidelines are essential for future clinical trials in PSS to accurately determine drug efficacy.
• While symptomatic treatments are available, effective disease-modifying therapies for PSS are still needed.
• Further research is required to establish best practices for managing severe PSS manifestations, especially lung disease.